Harvesting Cells for Experimental Cancer Treatments
The NCI Surgery Branch has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient.
This study will collect white blood cells from normal volunteers and white blood cells and/or tumor cells, from patients who have been screened for and are eligible for a NCI Surgery Branch treatment protocol. The cells collected from normal volunteers will be used as growth factors for the cells during the period of laboratory growth. The cells and/or tumor from patients will be used to make the cell treatment product.
Patients must be eligible for a NCI Surgery Branch Treatment Protocol
Normal Volunteers must meet the criteria for blood donation
Both patients and normal Volunteers will undergo apheresis. Patients will then undergo further testing as required by the treatment protocol.
There is no required follow up for normal volunteers.
|Study Design:||Time Perspective: Prospective|
|Official Title:||Cell Harvest and Preparation for Surgery Branch Adoptive Cell Therapy Protocols|
- To obtain autologous blood, stem cells and/or tumor tissue from patients currently with cancer for laboratory analysis and ex vivo generation of autologous anti-tumor lymphocytes for future enrollment on a Surgery Branch adoptive cell therapy cl... [ Time Frame: 15 years ] [ Designated as safety issue: No ]
|Study Start Date:||August 2003|
There are numerous clinical trials underway in the Surgery Branch, NCI in which patients are administered autologous lymphocytes with anti-tumor activity generated from either peripheral blood mononuclear cells (PBMC) or tumor infiltrating lymphocytes (TIL). All adoptive cell therapy protocols require that certain cell criteria be evaluated and met prior to enrollment.
- To obtain autologous blood, stem cells and/or tumor tissue from patients currently with cancer for laboratory analysis and ex vivo generation of autologous anti-tumor lymphocytes for future enrollment on a Surgery Branch adoptive cell therapy clinical trial, or for research purposes.
- To obtain autologous blood from patients with a history of cancer who currently have no evidence of disease for research purposes.
- To obtain allogeneic PBMC via apheresis, or blood samples from normal volunteers for use in generating anti-tumor patient lymphocytes ex vivo, or for research.
- To obtain PBMC via apheresis, blood samples, and skin biopsies from subjects with spontaneous vitiligo for research purposes.
- To conduct genomic, proteomic and immunologic research studies on samples collected.
Patients with cancer must be 16 years of age or older and meet the laboratory safety testing for infection included in all the cell therapy treatment trials.
Normal volunteers must meet the safety evaluation criteria established by the FDA for donation of blood products including HIV, HCV, HTLV, CMV, HBsAg, HBc, Trypanosoma cruzi, syphilis, and West Nile Virus. They must also meet the strict behavioral and medical history requirements.
Patients with a history of cancer who currently have no evidence of disease and subjects with spontaneous vitiligo must meet the laboratory safety testing for infection and other criteria outlined in the protocol.
Once a cancer patient is determined to be a potential candidate for one of the Surgery Branch clinical trials, they will undergo an apheresis and/or tumor resection for future treatment and/or research purposes. In addition, this protocol will allow for the pheresis of normal volunteers for allogeneic PBMC used in generating autologous anti-tumor lymphocytes in the laboratory, or for research purposes. This protocol will also allow for apheresis of patients with a history of cancer, and apheresis and , blood samples and skin biopsies in subjects with spontaneous vitiligo.
No treatments, investigational or standard therapy, will be administered on this protocol.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00068003
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Steven A Rosenberg, M.D.||National Cancer Institute (NCI)|